Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?